行情

INCY

INCY

因塞特医疗
NASDAQ

实时行情|Nasdaq Last Sale

97.25
-0.37
-0.38%
盘前: 96.35 -0.9 -0.93% 08:00 08/07 EDT
开盘
97.80
昨收
97.62
最高
98.50
最低
96.92
成交量
96.42万
成交额
--
52周最高
110.37
52周最低
62.48
市值
211.40亿
市盈率(TTM)
-106.7274
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INCY价格均价为105.73,最高价位132.00,最低价为87.00。

EPS

INCY 新闻

更多
Incyte Earnings Soar 65%, Easily Beating Views
Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance. INCY stock was not yet active early Tuesday.
Investor's Business Daily · 2天前
Incyte Corp (INCY) Q2 2020 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2020.
Motley Fool · 2天前
Incyte beats Q2 consesus; Jakafi sales +16% with guidance maintained
Incyte (INCY) Q2 results: Revenues: $688M (+29.8%); Jakafi: $473.7M (+16%); Iclusig: $22.8M (-7%); Jakavi product royalty: $66.2M (+16%); Olumiant product
seekingalpha · 2天前
Incyte EPS beats by $0.37, beats on revenue
Incyte (NASDAQ:INCY): Q2 Non-GAAP EPS of $1.24 beats by $0.37; GAAP EPS of $1.32 beats by $0.65. Revenue of $688.04M (+29.8% Y/Y) beats by $70.49M. Jakafi
seekingalpha · 2天前
Incyte shares are trading lower after the company reported its Q2 earnings results.
Benzinga · 2天前
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Zacks · 2天前
Dow Jones Today Dips, Nasdaq Fights To Extend Streak; Take-Two, SolarEdge, AMD Rocket
Take-Two, Inphi and Incyte rallied Tuesday, but stock futures dipped as the Dow Jones looked toward Disney's after-hours report.
Investor's Business Daily · 2天前
Incyte (INCY) Q2 Earnings and Revenues Beat Estimates
Incyte (INCY) delivered earnings and revenue surprises of 61.04% and 15.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3天前

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

INCY 简况

Incyte Corporation是一家生物医药公司。该公司专注于探索及开发医学治疗方案(主要为肿瘤治疗)并将其商业化。该公司专注于探索两面神激酶(JAK)抑制剂的研究及开发计划。该公司的产品包括不同研发阶段(前临床研究期及开发后期)的复方药以及已上市产品JAKAFI(ruxolitinib)。该公司已开发多种强效的、具有生物可用性的口服JAK抑制剂。其JAK抑制剂可以选择性抑制JAK1或抑制JAK1及JAK2。JAKAFI是在JAK计划中研制出的复方药,一种JAK1及JAK2的口服抑制剂。JAKAFI罕用药适用于骨髓纤维化(MF)、真性红细胞增多(PV)以及原发性血小板增多症。Baricitinib是该公司的第二种JAK1及JAK2口服抑制剂。
展开

微牛提供Incyte Corporation(NASDAQ-INCY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INCY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易INCY股票基本功能。